Arcus biosciences expands strategic relationship with wuxi biologics to develop a best-in-class anti-cd39 antibody for the treatment of cancer

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and wuxi biologics (2269.hk), a global company with leading open-access biologics technology platforms, today announced an expansion of their existing strategic relationship under which the parties will discover anti-cd39 antibodies using wuxi bio's proprietary technology. this cd39 collaboration represents the fourth antibody dev
RCUS Ratings Summary
RCUS Quant Ranking